- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04192513
Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo
A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison to Study the Safety and Antimicrobial Efficacy of DBI-001 Gel Vs. Placebo
Study Overview
Detailed Description
A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison. The goal is to determine the safety and tolerability of DBI-001 Gel vs. Placebo in Adults with Atopic Dermatitis and to determine the antibacterial effect of a single application of DBI-001 Gel on the abundance of S. aureus.
Tolerability will be evaluated through assessment of disease state severity and signs and symptoms of local tolerability (pain / burning / stinging, pruritus, erythema, edema, and scabbing / crusting) and review of adverse events. Any local skin reaction that requires use of a concomitant therapy or study discontinuation will be reported.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Santo Domingo, Dominican Republic
- Instituto Dermatologico y Cirugia de Piel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must meet all of the following criteria to be included in the study:
- Ability to understand, agree to, and sign the study Informed Consent. If the patient is unable to provide consent for him/herself, the patient's legally authorized representative may provide written consent.
- A signed Health Information Portability and Accountability Act (HIPAA) authorization form which permits the use and disclosure of subject's individually identifiable health information.
- Male or Female Subjects of any race 18 years of age and older.
- Physician diagnosed clinically stable Atopic Dermatitis according to the criteria of Hanifin and Rajka affecting ≤25% of total BSA with comparable bilateral antecubital or popliteal lesions. Each lesion must have an ADSI ≥6 with a difference between the lesions of ≤1. It will be in the opinion of the Investigator whether the lesions are clinically stable.
- Moderate to heavy growth of S. aureus based on culture at the time of screening.
- Willingness to discontinue use of other Atopic Dermatitis treatment for the duration of the study unless specifically permitted by the Investigator.
Women of child-bearing potential must:
- Have negative urine pregnancy tests prior to study treatment to rule out pregnancy, and
- Use at least one method of birth control that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner for the duration of study participation.
- Willingness not to wash the antecubital lesions on both arms, or the popliteal lesions on both legs, with soap and water from the time of test article application at baseline visit until after the completion of the Day 2 visit.
- Allow digital photos of arms or legs to be taken and stored.
Exclusion Criteria:
1. Women who are pregnant, planning a pregnancy, or breastfeeding or have a positive pregnancy test at the site.
2. Any dermatological conditions that could interfere with clinical evaluations or any disease state or physical condition which might expose the patient to an unacceptable risk by study participation.
3. Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy (see Points 5 and 6).
4. Known sensitivity to any of the components of the study medication. 5. Washout of 4 weeks for topical treatments used on the six designated sites, including but not limited to: antibacterial products, anti-inflammatories (e.g. corticosteroids, tacrolimus, Pimecrolimus). Other than the six sites on the arms or legs, topical mediations may be used before/during the duration of the study.
6. Willing not to apply any prescription or over the counter topical product on the selected designated sites on arms or legs.
7. Washout of 4 weeks for systemic treatments for AD, including but not limited to corticosteroids (oral or intramuscular injections), systemic immunomodulators or immunosuppressive (e.g., methotrexate, cyclosporine, hydroxychloroquine), antibiotics (oral or injected, if required to treat a medical condition short duration of oral antibiotics (≤10 days) are permitted after randomization).
8. Spontaneously improving or rapidly deteriorating dermatitis of the antecubital fossa or popliteal fossa.
9. Netherton's syndrome or other genodermatoses that result in defective epidermal barrier function.
10. Washout of 4 weeks for bleach baths. 11. Washout of 4 weeks for phototherapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cohort 1 DBI-001 Gel and placebo
Cohort 1 DBI-001 Gel with low dose CFU's of J. lividum and placebo
|
Investigational Product
Other Names:
|
Active Comparator: Cohort 2 mid dose DBI-001 Gel and placebo
Cohort 2 DBI-001 Gel with mid dose CFU's of J. lividum and placebo
|
Investigational Product
Other Names:
|
Active Comparator: Cohort 3 high dose DBI-001 Gel and placebo
Cohort 3 DBI-001 Gel with high dose CFU's of J. lividum.
Drug: J. lividum and placebo
|
Investigational Product
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Local Tolerability Based on Scale Listed
Time Frame: Baseline (Day 1) and 14
|
Tolerability will be evaluated through assessment of local signs and symptoms.
Scoring for burning, stinging, pruritus, erythema, edema, scabbing or crusting.
: 0+ none (complete absence), 1=slight (slight), 2=moderate (definitely present), 3=severe (marked, intense).
|
Baseline (Day 1) and 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in S. aureus abundance
Time Frame: 14 Days
|
Change in the abundance of S. aureus following a single application of DBI-001 Gel.
|
14 Days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Atopic Dermatitis signs and symptoms
Time Frame: 14 Days
|
Effect of signs and symptoms of Atopic Dermatitis after a single dose of DBI-001 Gel.
• Clinical evaluations will be done by the blinded evaluating investigator of test sites including the Atopic Dermatitis Severity Index (ADSI) and evaluation of erythema, pruritus, exudation, excoriation and lichenification.
Scoring: 0+ none (complete absence), 1=slight (slight), 2=moderate (definitely present), 3=severe (marked, intense).
|
14 Days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DBI-203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on J. lividum
-
DermBiont, Inc.CompletedTinea PedisDominican Republic
-
DermBiont, Inc.TerminatedInterdigital Tinea PedisDominican Republic
-
Radboud University Medical CenterCanisius-Wilhelmina Hospital; Johnson & Johnson Medical BV, The NetherlandsCompletedArthroplasty, Replacement, KneeNetherlands
-
International AIDS Vaccine InitiativeBrigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller UniversityActive, not recruitingHIV-1-infectionUnited States, Uganda, Kenya, Rwanda, South Africa
-
Ramos Mejía HospitalCompleted
-
Davidzon, Guido, M.D.Stanford UniversitySuspended
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingHIV-1-infectionMalawi, South Africa, Botswana
-
University of Wisconsin, MadisonNational Institute on Aging (NIA)Active, not recruiting
-
Minia UniversityCompleted
-
The Cleveland ClinicCompletedRectal CancerUnited States